Breast cancer is currently grouped into three main clinically relevant molecular subtypes: hormone receptor positive [estrogen receptor (ER+) and/or progesterone receptor (PR+)], human epidermal growth factor receptor positive (HER2+), and triple negative (TNBC) which is ER-, PR-, and HER2- [2]. Here, PGR is linked to breast carcinoma.